NZ602517A - Agent for treating disease - Google Patents

Agent for treating disease

Info

Publication number
NZ602517A
NZ602517A NZ602517A NZ60251709A NZ602517A NZ 602517 A NZ602517 A NZ 602517A NZ 602517 A NZ602517 A NZ 602517A NZ 60251709 A NZ60251709 A NZ 60251709A NZ 602517 A NZ602517 A NZ 602517A
Authority
NZ
New Zealand
Prior art keywords
chain
domain
composition
antibody
humanized anti
Prior art date
Application number
NZ602517A
Inventor
Matthias Germer
Frank Osterroth
Silke Aigner
Cristoph Uherek
Elmar Kraus
Andrea Wartenberg-Demand
Daniele Wolf
Sibylle Kaiser
Juergen Lindner
Christoph Bruecher
Benjamin Daelken
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0804684A external-priority patent/GB0804684D0/en
Priority claimed from GB0817810A external-priority patent/GB0817810D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of NZ602517A publication Critical patent/NZ602517A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is the use of a humanized anti-CD4 antibody capable of activating CD4+CD25+ regulatory T cells for the manufacture of a pharmaceutical composition for treating an autoimmune disease in a subject, wherein the humanized anti-CD4 antibody comprises an H chain V domain, an L chain V domain and an IgG 1 constant domain wherein: (a) the H chain V domain compnses the sequences DCRMY, VISVKSENYGANYAESVRG and SYYRYDVGAWFAY, and the L chain Vdomain compnses the sequences RASKSVSTSGYSYIY, LASILES and QHSRELPWT; and/or (b) the H chain V domain has at least 90% sequence identity with SEQ ID No: 1 and the L chain V domain has at least 90% sequence identity with SEQ ID No: 2, and wherein the composition is to be administered to the subject in a dose of the humanized anti-CD4 antibody of from 20 mg to 200 mg; 8 to 60 mg/m2 body surface area of the subject; or 0.2 to 2 mg/kg. Further disclosed is a pharmaceutical composition comprising the antibody as defined above wherein the composition is in a volume of 1 ml to 3 ml and the humanized anti-CD4 antibody is present in the composition at a concentration of from 20 to 150 mg/ml; or (ii) the composition is in a volume of 15 to 25 ml and the humanized anti-CD4 antibody is present in the composition at a concentration of approximately 10 mg/ml or approximately 12.5 mg/ml.
NZ602517A 2008-03-13 2009-03-10 Agent for treating disease NZ602517A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0804684A GB0804684D0 (en) 2008-03-13 2008-03-13 Humanized antibody
GB0817810A GB0817810D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
NZ58841409 2009-03-10

Publications (1)

Publication Number Publication Date
NZ602517A true NZ602517A (en) 2014-08-29

Family

ID=51582103

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ602517A NZ602517A (en) 2008-03-13 2009-03-10 Agent for treating disease

Country Status (1)

Country Link
NZ (1) NZ602517A (en)

Similar Documents

Publication Publication Date Title
MX2009006786A (en) Compositions and methods for the treatment of infections and tumors.
PH12017501075A1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
EP4378482A3 (en) Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
MX363819B (en) Cdim binding proteins and uses thereof.
NZ608502A (en) Polypeptides that bind to human complement component c5
TW200602078A (en) Uses of anti-CTLA-4 antibodies
MX2010010026A (en) Agent for treating disease.
NZ702800A (en) Methods and compositions for cns delivery of heparan n-sulfatase
MX2019000547A (en) Stabilized liquid and lyophilized adamts13 formulations.
MX339658B (en) Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase.
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
BRPI0512017A (en) optimized dosing with anti-cd4 antibodies for tolerance induction in primates
MX2014001370A (en) Cancer treatment and/or prevention drug composition.
JP2009521206A5 (en)
IN2012DN02826A (en)
WO2010132389A3 (en) Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
NZ594950A (en) Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
NZ595792A (en) Antibodies specific to cadherin-17
NZ603161A (en) Superior efficacy of cd37 antibodies in cll blood samples
NZ603196A (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
NZ594347A (en) Antibodies against human tweak and uses thereof
SG171674A1 (en) Methods of treating cancer by administering human il-18 combinations
RU2010136988A (en) ANTIGEN-BINDING POLYPEPTIDES AGAINST Cartilage Degeneration
WO2009072555A1 (en) Cancer vaccine

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 MAR 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20150105

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2017 BY CPA GLOBAL

Effective date: 20160129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2018 BY CPA GLOBAL

Effective date: 20170127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2019 BY CPA GLOBAL

Effective date: 20180125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2020 BY CPA GLOBAL

Effective date: 20190124

LAPS Patent lapsed